Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new study led by Weill Cornell Medicine suggests a surprising way to stop it from spreading. Researchers have discovered that an enzyme called EZH2 drives TNBC cells to divide abnormally, which enables them to relocate to distant organs. The preclinical study also found drugs that block EZH2 could restore order to dividing cells and thwart the spread of TNBC cells.

Researchers from Aarhus University have uncovered how cells in the cervix actively detect and combat infections. Using patient-derived mini-organs and advanced single-cell mapping, the study reveals a complex, coordinated defense network against pathogens like chlamydia. The findings pave the way for vaccines and treatments that boost local immune responses. The research is published in the scientific journal Science Advances.

Liver cirrhosis is significantly more common in low-income households than in high-income households. This is the result of a national study which, according to the researchers, calls for more preventive action in the most vulnerable groups.

October 3, 2025—BRONX, NY—Scientists at Montefiore Einstein Comprehensive Cancer Center (MECCC) and Albert Einstein College of Medicine have shown for the first time that glioblastoma—the deadliest form of brain cancer—affects not just the brain but also erodes the skull, alters the makeup of skull marrow, and interferes with the body’s immune response. Drugs intended to inhibit skull-bone loss made the cancer more aggressive, according to results published today in Nature Neuroscience.